The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers: 1321

@inproceedings{Rosenbaum2011TheST,
  title={The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers: 1321},
  author={David P Rosenbaum and Andrew G. Spencer and Jeffrey W. Jacobs and Dominique Campbell Charmot},
  year={2011}
}
Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: Focus on Prosecretory Agents
TLDR
Relatively small response rates, higher costs, and adverse effects associated with lubiprostone and linaclotide will likely render these agents suitable as second‐line therapies in the treatment of IBS‐C and CIC.
Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management
TLDR
Pharmacologic inhibition of gut NHE3 may be a viable strategy for managing sodium load in patients with CKD or with sodium-sensitive hypertension in general.
Non-Systemic Drugs: A Critical Review
  • D. Charmot
  • Medicine, Biology
    Current pharmaceutical design
  • 2012
TLDR
The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.